{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T02:43:21Z","timestamp":1776653001645,"version":"3.51.2"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Automated cross-sectional magnetic resonance imaging (MRI) measures of brain volume are becoming available in clinical practice; however, their prognostic utility in multiple sclerosis remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We investigated associations between cross-sectional brain and brain lesion volume measures and subsequent disability outcomes in relapsing\u2013remitting multiple sclerosis (RRMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicentre international cohort study using data collected prospectively in the MSBase Registry. MRI analysis was performed using icobrain ms. Associations between MRI volumetric measurements and confirmed disability worsening (CDW), progression independent of relapse activity (PIRA), secondary progressive multiple sclerosis (SPMS) and confirmed disability improvement (CDI) were examined using multivariable Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1598 patients were included and 68.6% received high-efficacy disease-modifying therapy during follow-up. Normalised lateral ventricular volume (mL) was significantly associated with all disability outcomes, including PIRA (hazard ratio 1.007; 95% confidence interval 1.002\u2009\u2212\u20091.012;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009). Higher normalised whole brain, grey matter and white matter volumes were all significantly associated with a lower hazard of CDW and higher hazard of achieving CDI. Higher normalised white matter volume was also significantly associated with a lower hazard of PIRA. Higher T1-weighted black hole lesion volume was significantly associated with an increased hazard of conversion to SPMS; lesion volume measures were otherwise not significantly associated with disability outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Automated MRI measures of brain volume from a single time point demonstrated prognostic utility in a highly treated cohort of people with RRMS. The results suggest that normalised lateral ventricular volume is a particularly informative prognostic marker across multiple disability outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-13788-z","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:19:25Z","timestamp":1775063965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cross-sectional brain volumetric measures and disability outcomes in relapsing\u2013remitting multiple sclerosis"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0614-1800","authenticated-orcid":false,"given":"Michael T. G.","family":"Hayes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3734-4133","authenticated-orcid":false,"given":"Heidi N.","family":"Beadnall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8766-3453","authenticated-orcid":false,"given":"Daniel","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-9768","authenticated-orcid":false,"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-7501","authenticated-orcid":false,"given":"Chao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Buzzard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Horakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Laureys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Lui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Lan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana M.","family":"Sima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Smeets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Vaneckova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Van Hecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Van Pesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-7003","authenticated-orcid":false,"given":"Anneke","family":"van der Walt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3940-8727","authenticated-orcid":false,"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"13788_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11910-002-0086-2","volume":"2","author":"M Filippi","year":"2002","unstructured":"Filippi M, Rocca MA, Rovaris M (2002) Clinical trials and clinical practice in multiple sclerosis: conventional and emerging magnetic resonance imaging technologies. Curr Neurol Neurosci Rep 2:267\u2013276. https:\/\/doi.org\/10.1007\/s11910-002-0086-2","journal-title":"Curr Neurol Neurosci Rep"},{"key":"13788_CR2","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1177\/1051228405283291","volume":"15","author":"R Zivadinov","year":"2005","unstructured":"Zivadinov R, Leist TP (2005) Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging 15:10S-21S. https:\/\/doi.org\/10.1177\/1051228405283291","journal-title":"J Neuroimaging"},{"key":"13788_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann T, Moccia M, Coetzee T et al (2023) Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol 22:78\u201388. https:\/\/doi.org\/10.1016\/S1474-4422(22)00289-7","journal-title":"Lancet Neurol"},{"key":"13788_CR4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1136\/jnnp-2012-304094","volume":"84","author":"V Popescu","year":"2013","unstructured":"Popescu V, Agosta F, Hulst HE et al (2013) Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 84:1082\u20131091. https:\/\/doi.org\/10.1136\/jnnp-2012-304094","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13788_CR5","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1136\/jnnp-2013-306906","volume":"85","author":"C Jacobsen","year":"2014","unstructured":"Jacobsen C, Hagemeier J, Myhr KM et al (2014) Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry 85:1109\u20131115. https:\/\/doi.org\/10.1136\/jnnp-2013-306906","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13788_CR6","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1177\/1352458516629769","volume":"22","author":"R Zivadinov","year":"2016","unstructured":"Zivadinov R, Uher T, Hagemeier J et al (2016) A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Mult Scler 22:1709\u20131718. https:\/\/doi.org\/10.1177\/1352458516629769","journal-title":"Mult Scler"},{"key":"13788_CR7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jamaneurol.2022.1025","volume":"79","author":"A Cagol","year":"2022","unstructured":"Cagol A, Schaedelin S, Barakovic M et al (2022) Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol 79:682\u2013692. https:\/\/doi.org\/10.1001\/jamaneurol.2022.1025","journal-title":"JAMA Neurol"},{"key":"13788_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41582-020-0314-x","volume":"16","author":"J Sastre-Garriga","year":"2020","unstructured":"Sastre-Garriga J, Pareto D, Battaglini M et al (2020) MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat Rev Neurol 16:171\u2013182. https:\/\/doi.org\/10.1038\/s41582-020-0314-x","journal-title":"Nat Rev Neurol"},{"key":"13788_CR9","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.neuroimage.2010.03.075","volume":"52","author":"MP Sampat","year":"2010","unstructured":"Sampat MP, Healy BC, Meier DS et al (2010) Disease modeling in multiple sclerosis: assessment and quantification of sources of variability in brain parenchymal fraction measurements. Neuroimage 52:1367\u20131373. https:\/\/doi.org\/10.1016\/j.neuroimage.2010.03.075","journal-title":"Neuroimage"},{"key":"13788_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.neuroimage.2016.07.035","volume":"142","author":"V Biberacher","year":"2016","unstructured":"Biberacher V, Schmidt P, Keshavan A et al (2016) Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis. Neuroimage 142:188\u2013197. https:\/\/doi.org\/10.1016\/j.neuroimage.2016.07.035","journal-title":"Neuroimage"},{"key":"13788_CR11","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1093\/brain\/awv258","volume":"138","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Cutter G, Spelman T et al (2015) Defining reliable disability outcomes in multiple sclerosis. Brain 138:3287\u20133298. https:\/\/doi.org\/10.1093\/brain\/awv258","journal-title":"Brain"},{"key":"13788_CR12","doi-asserted-by":"publisher","first-page":"e207768","DOI":"10.1212\/WNL.0000000000207768","volume":"102","author":"A Cagol","year":"2024","unstructured":"Cagol A, Benkert P, Melie-Garcia L et al (2024) Association of spinal cord atrophy and brain paramagnetic rim lesions with progression independent of relapse activity in people with MS. Neurology 102:e207768\u2013e207768. https:\/\/doi.org\/10.1212\/WNL.0000000000207768","journal-title":"Neurology"},{"key":"13788_CR13","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","volume":"80","author":"J M\u00fcller","year":"2023","unstructured":"M\u00fcller J, Cagol A, Lorscheider J et al (2023) Harmonizing definitions for Progression Independent of Relapse Activity in multiple sclerosis: a systematic review. JAMA Neurol 80:1232\u20131245. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3331","journal-title":"JAMA Neurol"},{"key":"13788_CR14","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/1352458517709619","volume":"24","author":"L Kappos","year":"2018","unstructured":"Kappos L, Butzkueven H, Wiendl H et al (2018) Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler 24:963\u2013973. https:\/\/doi.org\/10.1177\/1352458517709619","journal-title":"Mult Scler"},{"key":"13788_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Hollenbach JA, Bove R et al (2019) Silent progression in disease activity\u2013free relapsing multiple sclerosis. Ann Neurol 85:653\u2013666. https:\/\/doi.org\/10.1002\/ana.25463","journal-title":"Ann Neurol"},{"key":"13788_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1177\/1352458506070775","volume":"12","author":"H Butzkueven","year":"2006","unstructured":"Butzkueven H, Chapman J, Cristiano E et al (2006) MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler 12:769\u2013774. https:\/\/doi.org\/10.1177\/1352458506070775","journal-title":"Mult Scler"},{"key":"13788_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.nicl.2015.05.003","volume":"8","author":"S Jain","year":"2015","unstructured":"Jain S, Sima DM, Ribbens A et al (2015) Automatic segmentation and volumetry of multiple sclerosis brain lesions from MR images. Neuroimage Clin 8:367\u2013375. https:\/\/doi.org\/10.1016\/j.nicl.2015.05.003","journal-title":"Neuroimage Clin"},{"key":"13788_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2021.102707","volume":"31","author":"M Raki\u0107","year":"2021","unstructured":"Raki\u0107 M, Vercruyssen S, Van Eyndhoven S et al (2021) icobrain ms 5.1: Combining unsupervised and supervised approaches for improving the detection of multiple sclerosis lesions. NeuroImage Clin 31:102707. https:\/\/doi.org\/10.1016\/j.nicl.2021.102707","journal-title":"NeuroImage Clin"},{"key":"13788_CR19","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/wnl.59.5.688","volume":"59","author":"AB Rao","year":"2002","unstructured":"Rao AB, Richert N, Howard T et al (2002) Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b\">Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFN\u03b2-1b. Neurology 59:688\u2013694. https:\/\/doi.org\/10.1212\/wnl.59.5.688","journal-title":"Neurology"},{"key":"13788_CR20","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1136\/jnnp-2023-331748","volume":"94","author":"W Dzau","year":"2023","unstructured":"Dzau W, Sharmin S, Patti F et al (2023) Risk of secondary progressive multiple sclerosis after early worsening of disability. J Neurol Neurosurg Psychiatry 94:984\u2013991. https:\/\/doi.org\/10.1136\/jnnp-2023-331748","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13788_CR21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamaneurol.2025.0495","volume":"82","author":"J M\u00fcller","year":"2025","unstructured":"M\u00fcller J, Sharmin S, Lorscheider J et al (2025) Standardized definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA Neurol 82:614\u2013625. https:\/\/doi.org\/10.1001\/jamaneurol.2025.0495","journal-title":"JAMA Neurol"},{"key":"13788_CR22","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/brain\/aww173","volume":"139","author":"J Lorscheider","year":"2016","unstructured":"Lorscheider J, Buzzard K, Jokubaitis V et al (2016) Defining secondary progressive multiple sclerosis. Brain 139:2395\u20132405. https:\/\/doi.org\/10.1093\/brain\/aww173","journal-title":"Brain"},{"key":"13788_CR23","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1177\/13524585211000280","volume":"27","author":"BA Cree","year":"2021","unstructured":"Cree BA, Cohen JA, Reder AT et al (2021) Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. Mult Scler 27:2219\u20132231. https:\/\/doi.org\/10.1177\/13524585211000280","journal-title":"Mult Scler"},{"key":"13788_CR24","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/1352458513494490","volume":"20","author":"A Giorgio","year":"2014","unstructured":"Giorgio A, Stromillo ML, Bartolozzi ML et al (2014) Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis. Mult Scler 20:214\u2013219. https:\/\/doi.org\/10.1177\/1352458513494490","journal-title":"Mult Scler"},{"key":"13788_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/ene.13904","volume":"26","author":"I Dekker","year":"2019","unstructured":"Dekker I, Eijlers AJC, Popescu V et al (2019) Predicting clinical progression in multiple sclerosis after 6 and 12 years. Eur J Neurol 26:893\u2013902. https:\/\/doi.org\/10.1111\/ene.13904","journal-title":"Eur J Neurol"},{"key":"13788_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/archneurol.2011.765","volume":"69","author":"Z Caramanos","year":"2012","unstructured":"Caramanos Z, Francis SJ, Narayanan S, Lapierre Y, Arnold DL (2012) Large, nonplateauing relationship between clinical disability and cerebral white matter lesion load in patients with multiple sclerosis. Arch Neurol 69:89\u201395. https:\/\/doi.org\/10.1001\/archneurol.2011.765","journal-title":"Arch Neurol"},{"key":"13788_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3389\/fneur.2017.00433","volume":"8","author":"MA Rocca","year":"2017","unstructured":"Rocca MA, Comi G, Filippi M (2017) The role of T1-weighted derived measures of neurodegeneration for assessing disability progression in multiple sclerosis. Front Neurol 8:433. https:\/\/doi.org\/10.3389\/fneur.2017.00433","journal-title":"Front Neurol"},{"key":"13788_CR28","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1136\/jnnp.2007.124123","volume":"79","author":"A Minneboo","year":"2008","unstructured":"Minneboo A, Jasperse B, Barkhof F et al (2008) Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. J Neurol Neurosurg Psychiatry 79:917\u2013923. https:\/\/doi.org\/10.1136\/jnnp.2007.124123","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13788_CR29","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1212\/01.wnl.0000435551.90824.d0","volume":"81","author":"M Filippi","year":"2013","unstructured":"Filippi M, Preziosa P, Copetti M et al (2013) Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology 81:1759\u20131767. https:\/\/doi.org\/10.1212\/01.wnl.0000435551.90824.d0","journal-title":"Neurology"},{"key":"13788_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40263-014-0140-z","volume":"28","author":"N De Stefano","year":"2014","unstructured":"De Stefano N, Airas L, Grigoriadis N et al (2014) Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 28:147\u2013156. https:\/\/doi.org\/10.1007\/s40263-014-0140-z","journal-title":"CNS Drugs"},{"key":"13788_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/jnnp.2007.120378","volume":"79","author":"D Horakova","year":"2008","unstructured":"Horakova D, Cox JL, Havrdova E et al (2008) Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. J Neurol Neurosurg Psychiatry 79:407\u2013414. https:\/\/doi.org\/10.1136\/jnnp.2007.120378","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13788_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/ana.21436","volume":"64","author":"E Fisher","year":"2008","unstructured":"Fisher E, Lee JC, Nakamura K, Rudick RA (2008) Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 64:255\u2013265. https:\/\/doi.org\/10.1002\/ana.21436","journal-title":"Ann Neurol"},{"key":"13788_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200388","volume":"12","author":"M Ocampo-Pineda","year":"2025","unstructured":"Ocampo-Pineda M, Cagol A, Benkert P et al (2025) White matter tract degeneration in multiple sclerosis patients with progression independent of relapse activity. Neurol Neuroimmunol Neuroinflamm 12:e200388. https:\/\/doi.org\/10.1212\/nxi.0000000000200388","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13788_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/1531-8249(200003)47:3<391::AID-ANA20>3.0.CO;2-J","volume":"47","author":"N Evangelou","year":"2000","unstructured":"Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM (2000) Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 47:391\u2013395","journal-title":"Ann Neurol"},{"key":"13788_CR35","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/ene.12716","volume":"22","author":"T Uher","year":"2015","unstructured":"Uher T, Horakova D, Kalincik T et al (2015) Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon \u03b2-1a. Eur J Neurol 22:1113\u20131123. https:\/\/doi.org\/10.1111\/ene.12716","journal-title":"Eur J Neurol"},{"key":"13788_CR36","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.nicl.2017.06.022","volume":"15","author":"MG Dwyer","year":"2017","unstructured":"Dwyer MG, Silva D, Bergsland N et al (2017) Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. Neuroimage Clin 15:769\u2013779. https:\/\/doi.org\/10.1016\/j.nicl.2017.06.022","journal-title":"Neuroimage Clin"},{"key":"13788_CR37","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3174\/ajnr.A3086","volume":"33","author":"N Bergsland","year":"2012","unstructured":"Bergsland N, Horakova D, Dwyer MG et al (2012) Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 33:1573\u20131578. https:\/\/doi.org\/10.3174\/ajnr.A3086","journal-title":"AJNR Am J Neuroradiol"},{"key":"13788_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01473-3","volume":"403","author":"D Jakimovski","year":"2024","unstructured":"Jakimovski D, Bittner S, Zivadinov R et al (2024) Multiple sclerosis. Lancet 403:183. https:\/\/doi.org\/10.1016\/S0140-6736(23)01473-3","journal-title":"Lancet"},{"key":"13788_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.msard.2019.01.045","volume":"30","author":"FBS Briggs","year":"2019","unstructured":"Briggs FBS, Thompson NR, Conway DS (2019) Prognostic factors of disability in relapsing remitting multiple sclerosis. Mult Scler Relat Disord 30:9\u201316. https:\/\/doi.org\/10.1016\/j.msard.2019.01.045","journal-title":"Mult Scler Relat Disord"},{"key":"13788_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231221331","volume":"17","author":"H Butzkueven","year":"2024","unstructured":"Butzkueven H, Kalincik T, Patti F et al (2024) Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies. Ther Adv Neurol Disord 17:17562864231221331. https:\/\/doi.org\/10.1177\/17562864231221331","journal-title":"Ther Adv Neurol Disord"},{"key":"13788_CR41","doi-asserted-by":"publisher","first-page":"e1041","DOI":"10.1212\/wnl.0000000000010135","volume":"95","author":"MD Buron","year":"2020","unstructured":"Buron MD, Chalmer TA, Sellebjerg F et al (2020) Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study. Neurology 95:e1041\u2013e1051. https:\/\/doi.org\/10.1212\/wnl.0000000000010135","journal-title":"Neurology"},{"key":"13788_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-014-7340-9","volume":"262","author":"M Filippi","year":"2015","unstructured":"Filippi M (2015) MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment. J Neurol 262:1\u20136. https:\/\/doi.org\/10.1007\/s00415-014-7340-9","journal-title":"J Neurol"},{"key":"13788_CR43","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/jon.12553","volume":"28","author":"C Casserly","year":"2018","unstructured":"Casserly C, Seyman EE, Alcaide-Leon P et al (2018) Spinal cord atrophy in multiple sclerosis: a systematic review and meta-analysis. J Neuroimaging 28:556\u2013586. https:\/\/doi.org\/10.1111\/jon.12553","journal-title":"J Neuroimaging"},{"key":"13788_CR44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/ana.26281","volume":"91","author":"A Bischof","year":"2022","unstructured":"Bischof A, Papinutto N, Keshavan A et al (2022) Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis. Ann Neurol 91:268\u2013281. https:\/\/doi.org\/10.1002\/ana.26281","journal-title":"Ann Neurol"},{"key":"13788_CR45","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3174\/ajnr.A3503","volume":"34","author":"R Zivadinov","year":"2013","unstructured":"Zivadinov R, Bergsland N, Dolezal O et al (2013) Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. AJNR Am J Neuroradiol 34:1931\u20131939. https:\/\/doi.org\/10.3174\/ajnr.A3503","journal-title":"AJNR Am J Neuroradiol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13788-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13788-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13788-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T01:48:50Z","timestamp":1776649730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13788-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["13788"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13788-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"11 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michael Hayes has received travel support from Roche outside the submitted work. Heidi Beadnall has received speaker\u2019s honoraria and honoraria for attendance at advisory boards and travel sponsorship from Biogen, Merck, Novartis, Sanofi and Roche outside the submitted work. Daniel Merlo has received honoraria from Novartis outside the submitted work. Mastura Monif\u2019s university receives funding from National Health and Medical Research Council of Australia outside the submitted work. Ai-Lan Nguyen has\u00a0received research grants from Novartis, Biogen, Merck Serono and MS Research Australia; speaker honoraria from Roche, Biogen, Teva, Merck Serono and Novartis, and served on advisory boards for Merck Serono and Novartis outside the submitted work. Diana Sima and Dirk Smeets are employees of icometrix. Manuela Vaneckova has received speaker honoraria, consultant fees and travel expenses from Novartis, Roche, Merck, Biogen and has been supported by the Czech Ministry of Education\u2014project Cooperatio LF1, and National Institute for Neurological Research (Programme EXCELES, ID project No LX22NPO5107)\u2014funded by the European Union-Next Generation EU and Cooperatio LF1 and Ministry of Health\u2014institutional support, RVO 64165 outside the submitted work. Wim Van Hecke is CEO, founder, shareholder and member of the board of icometrix, and has received support from the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112153 (CLAIMS); the JU receives support from the European Union\u2019s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, AB Science SA and icometrix NV. Anneke van der Walt served on advisory boards for Novartis, Biogen, Merck, Roche and NervGen, received research grants from National Health and Medical Research Council of Australia, MS Research Australia, Novartis, Biogen, Merck and Roche, received speaker\u2019s honoraria and travel support from Novartis, Roche, Biogen and Merck. Helmut Butzkueven\u2019s institution has received compensation for advisory boards or lecture fees from Novartis, Biogen, Merck, UCB Pharma and Roche, and receives research funding from Novartis, Biogen, Merck, Roche, National Health and Medical Research Council of Australia, The Medical Research Future Fund (Australia), Monash Partners, Trish MS Foundation, The Pennycook Foundation, and MS Australia. He also receives personal compensation as the Managing Director of the MSBase Foundation and from the Oxford Health Policy Forum Brain Health Initiative. The remaining authors report no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The MSBase Registry (World Health Organization International Clinical Trials Registry Platform ID: ACTRN12605000455662) was approved by the Alfred Health Human Research Ethics Committee and by the local ethics committees in all participating centres. The study procedures were in accordance with the ethical guidelines of the Declaration of Helsinki. All participants provided written informed consent prior to their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"243"}}